Cargando…

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report

The treatment for AML (Acute myeloid/myelogenous leukemia) transformed from MDS (myelodysplastic syndrome) is difficult and controversial clinically, especially in elder patients. In this case report, we diagnosed a 59-year-old female patient with AML-M2a transformed form MDS which might be caused b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jin, Liu, Yu, Zhou, Xu, Li, Zheng, Li, Xiang, Xiao, Hualiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133025/ https://www.ncbi.nlm.nih.gov/pubmed/24696077 http://dx.doi.org/10.1007/s12013-014-9926-3

Ejemplares similares

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Bilateral Conjunctival Infiltration as an Extramedullary Relapse of AML
por: Mozaheb, Zahra, et al.
Publicado: (2018)

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT
por: Bohl, S, et al.
Publicado: (2016)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
por: Noviello, Maddalena, et al.
Publicado: (2019)

Granulocytic Sarcoma of the Uterus: A Rare Presentation of Extramedullary Relapse of AML and Importance of MRI
por: Ucar, Murat, et al.
Publicado: (2014)

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
por: Masetti, Riccardo, et al.
Publicado: (2023)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
por: Bhatnagar, Udit Bhaskar, et al.
Publicado: (2016)

Age-related epigenetic drift in the pathogenesis of MDS and AML
por: Maegawa, Shinji, et al.
Publicado: (2014)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
por: Li, Hongjiao, et al.
Publicado: (2023)

Successful Treatment of Gastric Relapse in Multiple Myeloma with Bortezomib after Autologous Hematopoietic Stem Cell Transplantation (autoHSCT)
por: Sivgin, Serdar, et al.
Publicado: (2013)

GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT
por: Wang, Dongyao, et al.
Publicado: (2022)

American Society of Hematology 2020 Podcast Collection: MDS and AML
por: Almeida, António
Publicado: (2021)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
por: Uy, Geoffrey L., et al.
Publicado: (2016)

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
por: Huang, Feiteng, et al.
Publicado: (2020)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
por: Chang, Lixian, et al.
Publicado: (2022)

DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
por: Jawad, Majd, et al.
Publicado: (2022)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
por: Raza, Azra, et al.
Publicado: (2020)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
por: Li, Hongjiao, et al.
Publicado: (2023)

Fulminant isolated adenovirus hepatitis 5 months after haplo-identical HSCT for AML
por: Detrait, Marie, et al.
Publicado: (2015)

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
por: Niscola, Pasquale, et al.
Publicado: (2015)

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML
por: Przychodzen, Bartlomiej, et al.
Publicado: (2017)

Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
por: Menshawy, Nadia El, et al.
Publicado: (2020)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
por: Rio-Machin, Ana, et al.
Publicado: (2020)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
por: Yiğit Kaya, Süreyya, et al.
Publicado: (2023)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center
por: Gao, Junyan, et al.
Publicado: (2022)

Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016)

Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature
por: Gao, Juehua, et al.
Publicado: (2014)

The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis
por: Yang, Yuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_furnbf7ovnlm9fcnvce7l7sp5b